The first MET inhibitor, crizotinib, was approved in 2011 for ALK-rearranged NSCLC and since that time, MET-targeted drugs including capmatinib and tepotinib have been approved for NSCLC harboring MET exon 14 skipping mutations. This evidence concerns the gene ALK and non-small cell lung carcinoma.